NEWS
- Pharma & Biotech News #PharmaBuzz
- Weekly News Recap #Phispers
- Recent Product Approvals #GreenLight
- Quality Compliance Alerts #Warning!
- All News #Library
DRUGS & DEVELOPMENTS
MARKET INTEL by PharmaCompass
Create content with us, ask us
By PharmaCompass
2018-11-29
Impressions: 202 Article
This week, Teva Pharmaceutical Industries launched its generic version of Mylan NV’s EpiPen at the wholesale price of US$ 300 for a pack of two auto-injectors. This is the same price as Mylan’s generic version of the emergency allergy shot. EpiPen auto-injectors deliver a dose of epinephrine in the event of a severe allergic reaction.
The Israeli drugmaker said its generic EpiPen is now available in limited supply in the US. It said additional supply, as well as a generic version of the lower-dose EpiPen Jr will be available next year.
In a statement issued post the announcement by Teva, FDA Commissioner Scott Gottlieb said: “We cannot control commercial decisions on pricing, (but) importantly, we have found that having three or more generic competitors brings prices down more sharply than with only one or two generic competitors.”
There has been a shortage of Mylan’s life-saving EpiPens. The company has blamed manufacturing issues at a Pfizer plant that supplies the EpiPens, for the shortage.
Back in 2016, Mylan’s EpiPen sales practices in the US sparked public outrage as the price of a pack of two auto-injectors rose six-fold to US$ 600 in less than a decade.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
